frontiers Frontiers in OncologyTYPE ReviewPUBLISHED 23 January 2023D0110.3389fonc2022.1096852Check for updatesExperts'consensus on theOPENACCESSdefinition and management ofEDITED BYCarolina Terragnahigh risk multiple myelomaSant'Orsola-Malpighi Polyclinic,ItalyREVIEWED BYCirino Botta,Chiara Marcon12,Valentina Simeon12,Paola Deias3,University of Palermo,ItalyXutao Guo,Gabriele Facchin',Alessandro Corso,Daniele DerudassSouthemn Medical University.ChinaVittorio Montefusco5,Massimo Offidani?,Maria Teresa PetrucciCORRESPOND ENCEChiara MarconRenato Zambello,Raffaella Stocchi',Renato Fanin12chimarcon@gmail.comand Francesca Patriarca12SP ECIALTY SECTIONDivision of Hematology.S.Maria della Misericordia Hospital Azienda Sanitaria Universitaria FriuliThis article was submitted toCentrale,Udine,Italy,2Department of Area Medica,Udine University.Udine,Italy.3Division ofHematologic Malignancies,Hematology and Bone Marrow Transplant Center,Department of Medical Science.R.Binaghi Hospitala section of the journalCagliari University.Cagliari Italy.Division of Hematology.Legnano's Hospital Milan,Italy.sDivision ofFrontiers in OncologyHematology and Bone Marrow Transplant Center,A.Businco Cancer Hospital Cagliari ltaly.DivisionRECEIVED 12 November 2022of Hematology.Azienda Socio Sanitaria Territoriale (ASST)Santi Paolo e Carlo,Milan,Italy,ClinicalACCEPTED 16 December 2022Hematology.Azienda Ospedaliera Universitaria (AOU)Ospedali Riuniti di Ancona,Ancona Italy.PUBUSHED 23 January 2023Division of Hematology.Department of Translational and Precision Medicine.Azienda OspedalieraPoliclinico Umberto l.Sapienza University of Rome,Rome.Italy.Cinical Hematology.AziendaCITATIONOspedaliera di Padova Padua ItalyMarcon C,Simeon V,Deias P,Facchin GCorso A,Derudas D.Montefusco V.Offidani M,Petrucci MT,Zambello R,Stocchi R.Fanin R and Patriarca F [2023)Experts'consensus on the definitionHigh risk multiple myeloma(HRMM)at diagnosis is currently recognized accordingand management of high riskto the Revised International Staging System(R-ISS)which was set up in 2015.Sincemultiple myelomaFont0nca.12:1096852then,new clinical and biological prognostic factors have been developed,whichdot:10.3389fonc.2022.1096852could implement the definition of High Risk(HR)category.We conducted a surveyCOPYRIGHTin order to identify which additional parameters,both clinical and biological,are2023 Marcon Simeon Deias,Facchinconsidered more useful for the clinical practice and to evaluate if the managementCorso,Derudas,Montefusco,OffidaniPetrucci Zambello,Stocchi,Fanin andof Multiple Myeloma (MM)should change on the basis of the risk category.APatriarca.This is an open-access articlequestionnaire,consisting of 8 statements,was submitted to 6 Italian experts,fromdistributed under the terms of the Creativethe European Myeloma Network(EMN)Research Italy,using the Delphi method.Commons Attribution License [CC BY).Theuse,dist ribution or reproduction in otherThe colleagues were asked to answer each question usin
